Skip to main content Back to Top
Advertisement

11/25/2019

Cefuroxime Sodium Injection

Products Affected - Description

    • Zinacef powder for solution for injection, Teligent, 1.5 gram, vial, 10 count, NDC 24987-0354-10 - discontinued
    • Zinacef powder for solution for injection, Teligent, 750 mg, vial, 10 count, NDC 24987-0352-10 - discontinued
    • Cefuroxime powder for solution for injection, Sagent, 750 mg, vial, 25 count, NDC 25021-0118-10

Reason for the Shortage

    • Sagent had cefuroxime injection on shortage due to manufacturing delays and increased demand.
    • Teligent discontinued all Zinacef presentations in February 2018.
    • Hikma did not provide a reason for the cefuroxime injection shortage. They are not currently marketing the 7.5 gram vials.

Available Products

    • Cefuroxime powder for solution for injection, Hikma, 1.5 gram, vial, 25 count, NDC 00143-9977-22
    • Cefuroxime powder for solution for injection, Hikma, 750 mg, vial, 25 count, NDC 00143-9979-22
    • Cefuroxime powder for solution for injection, Sagent, 1.5 gram, vial, 25 count, NDC 25021-0119-20

Estimated Resupply Dates

    • Sagent has cefuroxime 750 mg vials on allocation.
    • Teligent is estimating a relaunch of Zinacef 750 mg vials and 1.5 gram vials in February 2020.

Updated

Updated November 25, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 25, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins